Mural Oncology plc MURAV 深 沪
等待开盘 11-07 09:30:00 美东时间
150.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 150.00
- 总市值 0
- 52周最高 150.00
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 --
- 历史最高 150.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 65.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
WALTHAM, Mass. and DUBLIN, Ireland – Mural Oncology plc shareholders approved the acquisition by XRA 5 Corp., with over 99% of votes cast in favor at both the Scheme Meeting and Extraordinary General Meeting. Under the transaction, each Mural shareholder will receive a base cash price of $2.035 per share, with an additional potential $0.205 per share based on Closing Net Cash. The acquisition, valued at approximately $36.2 million, is expected to...
10-24 20:25
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
Mural Oncology announced the publication of its definitive proxy statement for shareholders regarding the acquisition by XOMA Royalty, which will be voted on at the Scheme Meeting and Extraordinary General Meeting on October 24, 2025, in Dublin. The proxy statement includes details of the acquisition terms, voting instructions, and the treatment of equity awards under the Irish Takeover Rules. Shareholders are urged to review the proxy statement,...
09-23 23:52
Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On?
Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin exploring strategic alternatives.
04-16 02:09
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.
03-25 21:28
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc ...
2024-12-04 05:16
Mural Oncology Appoints New Director and Audit Chair
Mural Oncology Plc ( ($MURA) ) has shared an announcement. Mural Oncology plc h...
2024-09-23 19:28
Mural Oncology Welcomes George Golumbeski as Director
Mural Oncology Plc (MURA) has provided an announcement. Mural Oncology plc anno...
2024-07-31 19:47
Mural Oncology plc GAAP EPS of -$3.57
Mural Oncology plc press release (NASDAQ:MURA): Q4 GAAP EPS of -$3.57. cash and cash equivalents were $270.9 million. More on Mural Oncology plc Recent Spin Mural Oncology At An Attractive Discount T...
2024-03-26 22:21
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational...
2024-01-08 08:00
Why Gap Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of The Gap, Inc. (NYSE: GPS) jumped in pre-market trading after the company reported better-than-expected financial results for the third quarter on Thursday.
2023-11-17 21:25
